Pharma Q3 Results Preview: Novartis, Lilly, Amgen, GSK

 
• By Sten Stovall, Mandy Jackson, and Lucie Ellis-Taitt
  
Generate a summary of this article
Listen to this article
Beta

There's optimism around Novartis as it heads into its final quarter with Joe Jimenez in charge, while Lilly faces impending headwinds, GSK will be touting Shingrix for future growth as vaccines growth tempers, and Amgen treads a complicated path through the biosimilar landscape.

Stage curtains
Financial Results: The Curtain Raiser • Source: Shutterstock

Change remains the theme at recently-revamped Novartis AG. Joe Jimenez, who has been CEO since 2010, in September said he'd step down Jan 31, 2018. His designated successor, Chief Medical Officer Vas Narasimhan, has vowed to cut drug development costs, saying savings of up to 25% are possible on expensive clinical trials as part of an increased focus on productivity. Narasimhan plans to partner with, or acquire, artificial intelligence and data analytics companies to supplement Novartis’s strong but scattered data science capability. Insights into these objectives will keep investors tuned in when Novartis gives its third-quarter results presentation on Oct 24. (Also see "Novartis CEO-Designate Set To Bring More Automation To Drug Discovery" - Scrip, 4 September, 2017.)

With the arrival of CAR-T therapies imminent, markets will be keen to hear how the Swiss group will turn its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.